Grassi Investment Management Has $62.31 Million Holdings in Eli Lilly and Company $LLY

Grassi Investment Management raised its position in shares of Eli Lilly and Company (NYSE:LLY) by 0.3% in the second quarter, HoldingsChannel reports. The firm owned 79,927 shares of the company’s stock after buying an additional 200 shares during the quarter. Eli Lilly and Company makes up 5.0% of Grassi Investment Management’s investment portfolio, making the stock its 5th largest position. Grassi Investment Management’s holdings in Eli Lilly and Company were worth $62,305,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in the business. WestEnd Advisors LLC grew its position in shares of Eli Lilly and Company by 210.0% during the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock valued at $26,000 after acquiring an additional 21 shares during the period. Wealth Preservation Advisors LLC bought a new stake in Eli Lilly and Company during the first quarter valued at about $27,000. Citizens National Bank Trust Department grew its holdings in Eli Lilly and Company by 180.0% during the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock valued at $35,000 after purchasing an additional 27 shares during the period. Financial Gravity Asset Management Inc. bought a new position in shares of Eli Lilly and Company during the 1st quarter valued at approximately $40,000. Finally, TD Capital Management LLC grew its stake in shares of Eli Lilly and Company by 129.2% during the 1st quarter. TD Capital Management LLC now owns 55 shares of the company’s stock valued at $46,000 after acquiring an additional 31 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Insider Activity at Eli Lilly and Company

In other news, Director Gabrielle Sulzberger bought 117 shares of the stock in a transaction dated Tuesday, August 12th. The stock was purchased at an average cost of $641.18 per share, for a total transaction of $75,018.06. Following the transaction, the director owned 2,703 shares of the company’s stock, valued at $1,733,109.54. The trade was a 4.52% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Daniel Skovronsky bought 1,000 shares of the stock in a transaction dated Tuesday, August 12th. The shares were purchased at an average price of $634.40 per share, with a total value of $634,400.00. Following the completion of the transaction, the executive vice president directly owned 137,660 shares in the company, valued at approximately $87,331,504. The trade was a 0.73% increase in their position. The disclosure for this purchase can be found here. Insiders purchased 4,514 shares of company stock valued at $2,894,841 in the last 90 days. 0.13% of the stock is currently owned by insiders.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY opened at $840.46 on Friday. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The firm has a fifty day moving average price of $734.60 and a 200 day moving average price of $766.47. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $937.00. The firm has a market cap of $795.47 billion, a price-to-earnings ratio of 54.93, a P/E/G ratio of 1.14 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter in the prior year, the firm earned $3.92 EPS. The business’s revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, sell-side analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

LLY has been the subject of a number of recent research reports. HSBC upgraded Eli Lilly and Company from a “reduce” rating to a “hold” rating and boosted their price objective for the company from $675.00 to $700.00 in a research note on Wednesday, August 27th. Morgan Stanley dropped their price target on shares of Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating for the company in a research report on Friday. UBS Group dropped their target price on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating for the company in a report on Friday, August 8th. Guggenheim dropped their target price on shares of Eli Lilly and Company from $942.00 to $875.00 and set a “buy” rating for the company in a report on Wednesday, August 13th. Finally, Deutsche Bank Aktiengesellschaft dropped their target price on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating for the company in a report on Monday, August 11th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus target price of $933.39.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.